Results 61 to 70 of about 578,179 (195)

Protein recruitment to receptor tyrosine kinase-mediated early signalling complexes. [PDF]

, 2007
Receptor tyrosine kinase (RTK) signalling regulates the activation of numerous cellular processes in response to various external stimuli. Spatio-temporal regulation of protein recruitment to activated tyrosine kinase receptors is important for the ...
Schller, A.C.
core  

Minimal residual disease–guided ibrutinib and venetoclax in patients with chronic lymphocytic leukaemia and complex karyotype

British Journal of Haematology, EarlyView.
Minimal residual disease (MRD)–guided ibrutinib and venetoclax (IVen) achieved durable remissions and high undetectable MRD (uMRD) rates in patients with high‐risk chronic lymphocytic leukaemia (CLL). Compared with historical ibrutinib monotherapy, IVen was associated with improved progression‐free and overall survival despite presence of complex ...
Maria Kislova, Elena Dmitrieva, Elena Naumova, Margarita Pochtar, Svetlana Lugovskaya, Yury Kobzev, Alla Loban, Maria Gladysheva, Tatiana Obukhova, Bella Biderman, Andrey Sudarikov, Egor Volchkov, Maria Ivanova, Vadim Ptushkin, Andrea Visentin, Eugene Nikitin   +15 more
wiley   +1 more source

SAKK 35/14 randomized trial of rituximab with or without ibrutinib for patients with untreated follicular lymphoma

British Journal of Haematology, EarlyView.
Summary The randomized phase II SAKK 35/14 trial, conducted by the Swiss Group for Clinical Cancer Research (SAKK) and the Nordic Lymphoma Group (NLG), compared efficacy and safety of rituximab (375 mg/m2 intravenously for 4 weeks followed by maintenance every 2 months for 24 months) plus placebo (arm A) versus the same schedule of rituximab plus ...
Maria Cristina Pirosa, Marianne Brodtkorb, Sämi Schär, Björn E. Wahlin, Micaela Hernberg, Michael Pedersen, Anastasios Stathis, Thilo Zander, Urban Novak, Thorsten Zenz, Natalie Fischer, Fatime Krasniqi, Felicitas Hitz, Ann‐Sofie Johansson, David Löfgren, Peter Albert Meyer, Anne Turid Bjørnevik, Giulio Sartori, Stefanie Hayoz, Andrea Fuhrer, Luzia Steiner, Francesco Bertoni, Luca Ceriani, Stefan Dirnhofer, Emanuele Zucca, Bjørn Østenstad   +25 more
wiley   +1 more source

Bruton’s tyrosine kinase is a possible therapeutic target in microscopic polyangiitis

Arthritis Research & Therapy, 2023
Background Bruton’s tyrosine kinase (Btk) is an enzyme expressed in leukocytes other than T lymphocytes and plasma cells and involved in B-cell receptor- and Fcγ receptor (FcγR)-mediated signal transduction.
Issei Nakade, Yuto Tamura, Fuyu Hashimoto, Yuko Ariza, Shingo Hotta, Hirofumi Fujigaya, Suishin Arai, Mai Taniguchi, Hodaka Ogawa, Yuka Nishibata, Sakiko Masuda, Daigo Nakazawa, Utano Tomaru, Akihiro Ishizu   +13 more
doaj   +1 more source

Targeting Solid Tumors With BTK Inhibitors

Frontiers in Cell and Developmental Biology, 2021
The repurposing of FDA-approved Bruton’s tyrosine kinase (BTK) inhibitors as therapeutic agents for solid tumors may offer renewed hope for chemotherapy-resistant cancer patients.
Fatih M. Uckun, Taracad Venkatachalam
doaj   +1 more source

Ibrutinib versus allogeneic haematopoietic stem cell transplant in relapsed/refractory del(17p) chronic lymphocytic leukaemia/small lymphocytic lymphoma

British Journal of Haematology, EarlyView.
After adjusting for confounders, the ibrutinib cohort had significantly better overall survival (adjusted hazard ratio, 0.39; 95% confidence interval, 0.23–0.68; p = 0.0008) than the allogeneic haematopoietic stem cell transplantation (alloHSCT) cohort.
Farrukh T. Awan, Ran Liu, Hsin‐Hui Huang, Matthew Bye, Kwang Woo Ahn, Gabriel Krigsfeld, Anat Raz, Heather Wolfe, Mehdi Hamadani   +8 more
wiley   +1 more source

Tyrosine phosphorylation of myosin heavy chain during skeletal muscle differentiation: an integrated bioinformatics approach [PDF]

, 2005
Background: Previously it has been shown that insulin-mediated tyrosine phosphorylation of myosin heavy chain is concomitant with enhanced association of C-terminal SRC kinase during skeletal muscle differentiation. We sought to identify putative site(s)
RJ Edwards, Harney, D.F., Richard J. Edwards (7949342), DF Harney, Ryan K. Butler (7949339), Donal F. Harney (7949336), Butler, R., Edwards, Richard J., RK Butler   +8 more
core   +1 more source

Advancements in research on the cardiovascular toxicity caused by TEC family kinases inhibitors

Frontiers in Pharmacology
The tyrosine kinase expressed in hepatocellular carcinoma (TEC) family kinases (TFKs) are a subfamily of non-receptor protein tyrosine kinases (PTKs) that include five members: TEC, bruton’s tyrosine kinase (BTK), interleukin 2-inducible T-cell kinase ...
Yi Zhang, Huangxi Fu, Xingchen Kang, Zixuan Qiu, Hao Yan, Qiaojun He, Qiaojun He, Qiaojun He, Bo Yang, Bo Yang, Bo Yang, Zhifei Xu, Peihua Luo, Peihua Luo   +13 more
doaj   +1 more source

Bruton’s tyrosine kinase regulates gut immune homeostasis through attenuating Th1 response

Cell Death and Disease, 2021
Inflammatory bowel disease (IBD) is driven by multiple genetic and environmental risk factors. Patients with mutations in Bruton’s tyrosine kinase (BTK) is known to manifest high prevalence of intestinal disorders including IBD. Although BTK mediates the
Di Guan, Zixi Wang, Jianxin Huo, Shengli Xu, Kong-Peng Lam   +4 more
doaj   +1 more source

Bruton’s Tyrosine Kinase: An Emerging Key Player in Innate Immunity

Frontiers in Immunology, 2017
Bruton’s tyrosine kinase (BTK) was initially discovered as a critical mediator of B cell receptor signaling in the development and functioning of adaptive immunity.
Alexander N. R. Weber, Zsofia Bittner, Xiao Liu, Truong-Minh Dang, Markus Philipp Radsak, Cornelia Brunner   +5 more
doaj   +1 more source